McKesson Corporation $MCK Shares Sold by Pictet Asset Management Holding SA

Posted by George Bondi on Jun 29th, 2026

Pictet Asset Management Holding SA cut its holdings in shares of McKesson Corporation (NYSE:MCK – Free Report) by 8.5% during the first quarter, Holdings Channel.com reports. The institutional investor owned 116,739 shares of the company’s stock after selling 10,836 shares during the period. Pictet Asset Management Holding SA’s holdings in McKesson were worth $101,014,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Brighton Jones LLC grew its stake in McKesson by 46.3% during the 4th quarter. Brighton Jones LLC now owns 2,523 shares of the company’s stock worth $1,438,000 after purchasing an additional 798 shares in the last quarter. Caxton Associates LLP acquired a new position in shares of McKesson during the first quarter worth about $233,000. Sivia Capital Partners LLC increased its stake in shares of McKesson by 77.9% during the second quarter. Sivia Capital Partners LLC now owns 685 shares of the company’s stock worth $502,000 after buying an additional 300 shares during the period. Treasurer of the State of North Carolina raised its holdings in McKesson by 0.9% in the second quarter. Treasurer of the State of North Carolina now owns 58,623 shares of the company’s stock valued at $42,958,000 after acquiring an additional 508 shares in the last quarter. Finally, Osterweis Capital Management Inc. purchased a new position in McKesson in the second quarter worth approximately $166,000. Institutional investors and hedge funds own 85.07% of the company’s stock.

Insider Transactions at McKesson

In related news, CEO Brian S. Tyler sold 8,463 shares of the company’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $775.13, for a total value of $6,559,925.19. Following the completion of the sale, the chief executive officer owned 14,382 shares in the company, valued at $11,147,919.66. This represents a 37.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michele Lau sold 3,550 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $761.09, for a total transaction of $2,701,869.50. Following the sale, the executive vice president owned 3,247 shares of the company’s stock, valued at approximately $2,471,259.23. This represents a 52.23% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 20,285 shares of company stock valued at $15,546,137 over the last ninety days. 0.06% of the stock is owned by insiders.

Analysts Set New Price Targets

MCK has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $875.00 price objective on shares of McKesson in a report on Friday, May 8th. Citigroup decreased their price target on McKesson from $975.00 to $945.00 and set a “buy” rating for the company in a report on Thursday, May 14th. Weiss Ratings downgraded McKesson from a “buy (b+)” rating to a “buy (b)” rating in a report on Monday, May 18th. William Blair began coverage on McKesson in a research report on Tuesday, April 28th. They set an “outperform” rating on the stock. Finally, JPMorgan Chase & Co. lowered their price target on McKesson from $1,107.00 to $1,015.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Fourteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $960.53.

Check Out Our Latest Analysis on McKesson

McKesson Price Performance

NYSE MCK opened at $764.38 on Monday. The company has a fifty day moving average of $777.55 and a two-hundred day moving average of $840.59. The company has a market capitalization of $89.49 billion, a PE ratio of 19.87, a P/E/G ratio of 1.26 and a beta of 0.31. McKesson Corporation has a 1 year low of $637.00 and a 1 year high of $999.00.

McKesson (NYSE:MCK – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported $11.69 earnings per share for the quarter, beating the consensus estimate of $11.56 by $0.13. The business had revenue of $96.30 billion during the quarter, compared to the consensus estimate of $101.35 billion. McKesson had a negative return on equity of 345.35% and a net margin of 1.18%.The business’s quarterly revenue was up 6.0% on a year-over-year basis. During the same period in the previous year, the business earned $10.12 EPS. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. On average, research analysts expect that McKesson Corporation will post 44.28 earnings per share for the current year.

McKesson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 1st. Stockholders of record on Monday, June 1st will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, June 1st. McKesson’s dividend payout ratio is presently 8.53%.

McKesson Company Profile

(Free Report)

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.